- Home
- IONS
as 09-05-2025 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.8B | IPO Year: | 1991 |
| Target Price: | $67.88 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $62.08 | Next Earning Date: | 07-30-2025 |
| Revenue: | $944,050,000 | Revenue Growth: | 16.05% |
| Revenue Growth (this year): | 24.3% | Revenue Growth (next year): | 7.39% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LOSCALZO JOSEPH | IONS | Director | Sep 3 '25 | Sell | $60.15 | 32,000 | $1,924,742.40 | 36,330 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Sep 3 '25 | Sell | $60.55 | 32,800 | $1,946,220.28 | 31,926 | |
| Monia Brett P | IONS | Chief Executive Officer | Sep 3 '25 | Sell | $60.11 | 203,814 | $12,294,703.00 | 180,824 | |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Sep 3 '25 | Sell | $60.94 | 39,316 | $2,390,841.75 | 51,507 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Sep 3 '25 | Sell | $60.62 | 67,818 | $4,111,127.16 | 101,570 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Sep 3 '25 | Sell | $61.16 | 153,700 | $9,370,850.50 | 5,655 | |
| WENDER JOSEPH H | IONS | Director | Sep 3 '25 | Sell | $60.14 | 22,400 | $1,347,097.92 | 108,835 | |
| KLEIN JOSEPH III | IONS | Director | Sep 3 '25 | Sell | $60.00 | 56,000 | $3,360,000.00 | 0 | |
| Devers Shannon L. | IONS | EVP, Chief Human Resources Ofc | Sep 3 '25 | Sell | $61.02 | 3,162 | $192,942.71 | 15,009 | |
| Swayze Eric | IONS | EVP Research | Sep 2 '25 | Sell | $51.45 | 11,130 | $552,861.68 | 38,432 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Benzinga
16 days ago
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
MT Newswires
16 days ago
Ionis Pharmaceuticals Says Hereditary Angioedema Therapy Approved by US FDA
Business Wire
16 days ago
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Insider Monkey
2 months ago
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
GlobeNewswire
2 months ago
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Investor's Business Daily
2 months ago
Can Biogen Save Even More Kids With This New Drug?
MT Newswires
2 months ago
Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.